434 results on '"Kreuzer, K. A."'
Search Results
2. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
3. Leukämien: Fortschritt in der Diagnostik im Kontext der minimalen Resterkrankung
4. A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX COMPARED TO OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA
5. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)
6. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
7. Soil bacteria and protozoa affect root branching via effects on the auxin and cytokinin balance in plants
8. S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
9. S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB
10. Zufallsbefund Lymphozytose: Von der Normvariante bis zur Leukämie
11. Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors: 34
12. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
13. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
14. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
15. Interactions between arbuscular mycorrhizal fungi ( Glomus intraradices, Glomeromycota) and amoebae ( Acanthamoeba castellanii, Protozoa) in the rhizosphere of rice ( Oryza sativa)
16. Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial: 36
17. GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL
18. THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION
19. BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG
20. VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY
21. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY
22. A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany: ID 461
23. Screening supported by a central review allows a precise selection of the population for maintenance therapy within the CLLM1 trial of the German CLL Study Group: ID 219
24. Long Term Remissions After FCR Chemoimmunotherapy In Patients With CLL: ID 500
25. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique
26. Grazing of a common species of soil protozoa ( Acanthamoeba castellanii) affects rhizosphere bacterial community composition and root architecture of rice ( Oryza sativa L.)
27. Endogenous levels of C-C chemokines MIP-1α, MIP-1β, and RANTES do not reflect the disease course in HIV-seropositive individuals
28. A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: V720
29. Leukämien
30. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY.
31. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL.
32. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort
33. Leberveränderungen bei AIDS Retrospektive Analyse von 227 Sektionen HIV-positiver Patienten: Retrospektive Analyse von 227 Sektionen HIV-positiver Patienten
34. Reduced incidence of pneumonia and invasive pulmonary aspergillosis after introduction of posaconazole prophylaxis - data from the cologne AML Cohort: O3.6
35. The CLL-RT1 trial : A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation
36. Pathogenesis and pathophysiology of anemia in HIV infection
37. Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection
38. Successful allogeneic stem cell transplantation from a matched sibling donor after previous partial liver transplantation from the same donor
39. High-dose intravenous immunoglobulins in the treatment of adolescent and adult HIV-infected hemophiliacs
40. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
41. Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized phase 3 CLL14 trial.
42. Patients with haematological malignancies show a restricted body image focusing on function and emotion
43. Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML
44. Activity and pharmacokinetics of CG P74588 the main metabolite of Imatinib: P640
45. Early and sensitive detection of primary and secondary resistance to imatinib mesylate in chronic myelogenous leukemia by a novel PNA based PCR clamping assay: 776
46. Simultaneous quantification of BCR-ABL Transcripts and T-Cell Receptor excision circles after allogeneic bone marrow transplantation: 36
47. Imatinib (STI571) pharmacokinetics in patients with CML: 21
48. Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia
49. Chloropropanols in paper straws – a health risk?
50. Vielfältige Vertriebsmodelle
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.